SCHEMBL15134366

SCHEMBL15134366

CCc1cnn(CCN2CCN(C)CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 3/20 0.41
HTR7 P34969 1/20 0.38
FGFR3 P22607 1/20 0.38
MC4R P32245 1/20 0.36
SIGMAR1 Q99720 5/20 0.36
HRH3 Q9Y5N1 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
PAICS P22234 1/20 0.35
LMNA P02545 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
KDM1A O60341 1/20 0.33
IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10263495 0.88 HRH3 (0.46) TLR7SIGMAR1HRH3CYP1A2CYP2D6
SCHEMBL9908370 0.85 TLR7 (0.42) TLR7SIGMAR1HRH3CYP1A2LMNA
SCHEMBL17145798 0.84 IGF1R (0.36) TLR7FGFR3LMNADRD3IGF1R
SCHEMBL21983919 0.84 FGFR3 (0.40) TLR7FGFR3SIGMAR1HRH3CYP1A2
SCHEMBL23205120 0.81 KDM1A (0.38) TLR7SIGMAR1KDM1A
SCHEMBL12285332 0.79 NOS3 (0.38) TLR7HTR7FGFR3MC4RSIGMAR1
SCHEMBL522038 0.78 LMNA (0.42) TLR7FGFR3MC4RSIGMAR1HRH3
SCHEMBL15507805 0.78 PAICS (0.38) TLR7FGFR3MC4RSIGMAR1HRH3
SCHEMBL14725170 0.77 HTR7 (0.40) TLR7HTR7FGFR3MC4RSIGMAR1
SCHEMBL18390903 0.77 LMNA (0.47) MC4RHRH4LMNADRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140228349-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES ARRAY BIOPHARMA, INC. 2014-08-14 US disclosed
US-20130190305-A1 NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228349-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES JAK1, JAK3, JAK2 TLR7 170/4885HTR7 1509/4885FGFR3 665/4885
US-20130190305-A1 NEW 5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLINES AS IGF-1R/IR INHIBITORS IGF1R, IGFBP1, INSR TLR7 1726/4885HTR7 664/4885FGFR3 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.